Table 1 Epidemiological and clinical characteristics of study population

Number, n

45

28

19

Age, years, mean (SD)

46 (13)

51 (13)

46 (16)

Female/male, n/n (% female)

38/7 (84)

27/1 (97)

13/6 (68)

Serostatus, n/n

AQP4-IgG

n.a

28/28

0/19

MOG-IgG

n.a

0/28

19/19

Time from disease onset to visit, years, median (IQR)

n.a

8.4 (2.7–9.8)

4.5 (1.7–7)

ARR median (range)

Number of patients with at least 1 attack during previous year, n (%)

n.a

n.a

0.39 (0.12–4.94)

5 (18)

0.73 (0.12–3.38)

7 (37)

Type of last attack, n (%)

Optic neuritis

n.a

2 (7)

4 (21)

Myelitis

Brainstem encephalitis

n.a

n.a

3 (11)

0 (0)

2 (11)

1 (6)

EDSS, median (IQR)

n.a

3(2–4)

2 (1.5–3.5)

Immunotherapy, n/n (%)

No:45/45 (100)

No:6/28 (21)

Any:22/28 (79)

RTX:14/28 (50) AZA:6/28 (21) MMF:2/28 (7) TCZ:1/28 (3) ECU:1/28 (3)

No:5/19 (26)

Any:14/19 (74) RTX:8/19 (42) AZA:1/19 (10) MMF:2/19 (10) TCZ:1/19 (5) MTX:1/19 (5)

IVIG:1/19 (5)

Concomitant autoimmune disease, n/n (%)

n.a

7/28 (25)

1/19 (5)

SLE

n.a

4/28 (14)

0/19 (0)

Sjögren syndrome

n.a

2/28 (7)

0/19 (0)

Myasthenia gravis

n.a

2/28 (7)

0/19 (0)

Autoimmune thyroiditis

n.a

2/28 (7)

1/19 (5)